(Cary, N.C.) Industry Standard Research (ISR) today announced the release of a new report titled “The State of Clinical Imaging” in which 36 pharmaceutical sponsor decision-makers provide their usage, insights, and forecasts regarding the clinical imaging market by rating 98 service provider encounters. (more…)

(Kannapolis, N.C.) From the consumer point of view, deciphering health benefits amidst a sea of brands, colors, styles, types, flavors, health claims and price points is difficult.  At least that’s what a consumer panel conducted at Sensory Spectrum’s North Carolina Discovery Center concluded when evaluating yogurt as a healthy snack. (more…)

(Cary, N.C.) Industry Standard Research (ISR) today announced the release of a new report titled “The State of the ECG Market in Clinical Trials” in which 79 pharmaceutical sponsor decision-makers provide their insights and forecasts regarding the ECG market by rating 286 service provider encounters. (more…)

(Research Triangle Park, N.C.) In the next several weeks, pharmaceutical, biotechnology and medical device companies will have to start compiling data on their physician expenditures to meet the requirements spelled out in the Physician Payments Sunshine Provision of the Patient Protection and Affordable Care Act. However, the U.S. government has yet to provide drug and device manufacturers with detailed guidelines on how to submit the information or how the data will be made public. (more…)

(Research Triangle Park, N.C.) Drug companies allocated 13 percent of their average total market access budgets to patient-reported outcomes teams this year, according to new benchmarking data from Cutting Edge Information. 57 percent of profiled companies will increase their PRO team budgets in 2012 and no profiled company will be decreasing its PRO budget next year. (more…)

(Durham, N.C.) PharPoint Research, Inc., a leading drug development service provider offering biotechnology and pharmaceutical companies expertise in project management, clinical monitoring, data management and biostatistics services, announces that PharPoint Research was recognized by Triangle Business Journal as one of the 50 fastest growing companies in the Triangle area. The Fast 50 winners were selected and ranked based on a formula that counts revenue growth and profitability in the preceding three years (2008-2010). Art Holmes, the company’s President and CEO, commented, “This award is a testament to our company’s commitment to superb quality and client satisfaction. By focusing on these two areas, in the past 12 months we have been able to grow the company’s size by over 45% to offer even more services to better serve our clients.” (more…)

(Cary, N.C.) INC Research, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, and SAS are working together to improve clinical development risk management and achieve targeted product profiles through analytics. Collaborating with SAS, the leader in health analytics software and services, INC Research will offer biopharmaceutical customers an integrated suite of tools to increase decision-making speed, efficiency and flexibility. The ultimate goal is to improve a customer’s ability to manage risk, control investment and maximize ROI in clinical development. (more…)

(Charlotte, N.C.) Falfurrias Capital Partners, a Charlotte-based private equity firm, today announced it has invested as a strategic partner in Dorsey Wright & Associates, a Richmond, Va.-based provider of technical investment research and money management products. Falfurrias Capital, founded by former Bank of America Chairman and CEO Hugh McColl Jr. and former Bank of America CFO Marc D. Oken, has been actively targeting investments in the financial services industry. (more…)

(Research Triangle Park, N.C.) New research shows that virtually all drug research companies are planning to maintain or increase spending for market access activities in 2012. Budgeting may be fine-tuned and reallocated, but companies are cutting very little, if any, resources for these activities, the benchmarking study by Cutting Edge Information shows. In fact, most market access categories will see increased funding at more than 50 percent of drug companies next year. (more…)

(Durham, N.C.) Researchers at Duke University Medical Center have discovered a way to block the damaging actions of chlamydia, the bacteria responsible for the largest number of sexually transmitted infections in the United States. The team, which included Duke University microbiologists and chemists, designed a molecule that takes away the bacteria’s self-defense mechanisms. (more…)

(Durham, N.C.) Duke researchers have deciphered what sustains new neuron production in the adult brain, a “fountain of youth” in rodents that is also believed to be present in the human brain. Importantly, this likely explains why stem cells removed from the adult brain and placed in culture can’t continue to generate neurons over time, a major road block in using these stem cells for injury repair. (more…)

(Whitehouse Station, N.J., & Chapel Hill, N.C.) Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS. (more…)